GalNAc-TL4 Inhibitors
GalNAc-TL4 Inhibitors are a class of compounds that either directly or indirectly inhibit the glycosyltransferase activity of GalNAc-TL4. Benzyl-α-GalNAc is a direct inhibitor, acting as a competitive substrate analog. It competes with natural substrates for the catalytic site of GalNAc-TL4, resulting in the inhibition of the enzyme's activity in initiating and elongating mucin-type O-glycosylation. Other inhibitors like acarbose and swainsonine work indirectly; acarbose alters the glycosylation pattern by inhibiting α-glucosidase, thereby influencing the availability of substrates for GalNAc-TL4. Swainsonine targets α-mannosidase II, leading to abnormal glycosylation that may sequester GalNAc-TL4 away from its typical glycoprotein targets, thus indirectly inhibiting its function.
Compounds such as tunicamycin, castanospermine, deoxynojirimycin, and deoxymannojirimycin can disrupt the glycosylation processing pathways, leading to a reduced pool of properly folded glycoproteins for GalNAc-TL4 to act upon. Tunicamycin, for instance, inhibits N-linked glycosylation by blocking the transfer of N-acetylglucosamine (GlcNAc) to dolichol phosphate, which is an essential early step in the synthesis of glycoproteins. As a result, the inhibition of N-linked glycosylation can lead to an overall decrease in the glycoprotein substrates that are necessary for GalNAc-TL4's activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside | 3554-93-6 | sc-203427 sc-203427A | 100 mg 1 g | $350.00 $3184.00 | 2 | |
Benzyl-α-GalNAc acts as a substrate analog inhibitor for GalNAc-transferases, including GalNAc-TL4. It competes with endogenous substrates for the active site, thereby inhibiting the enzymatic activity of GalNAc-TL4 in glycosylation processes. | ||||||
Acarbose | 56180-94-0 | sc-203492 sc-203492A | 1 g 5 g | $226.00 $605.00 | 1 | |
This α-glucosidase inhibitor can indirectly inhibit GalNAc-TL4 by altering glycosylation patterns, since altered upstream sugar processing can impact the substrate availability for GalNAc-TL4 catalyzed reactions. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation by blocking the formation of dolichol-linked oligosaccharides. As a result, it can indirectly inhibit GalNAc-TL4 by disrupting the overall glycosylation homeostasis within the cell. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
As an inhibitor of α-mannosidase II, swainsonine leads to aberrant glycosylation which can indirectly inhibit GalNAc-TL4 by sequestration through misfolded glycoproteins or altered glycan processing pathways. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
This glucosidase inhibitor can lead to glycoprotein misfolding and altered glycan processing, which may indirectly inhibit GalNAc-TL4 by affecting the pool of glycoproteins available for O-glycosylation. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Deoxynojirimycin inhibits glucosidases and can result in misfolded glycoproteins with high mannose content. This may sequester GalNAc-TL4, limiting its interaction with proper glycosylation substrates. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
Similar to deoxynojirimycin, this compound inhibits mannosidase, leading to a build-up of high-mannose glycoproteins that might indirectly inhibit GalNAc-TL4 by altering the substrate specificity. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
This mannosidase inhibitor can increase the high-mannose glycan pool, potentially sequestering GalNAc-TL4 and inhibiting its normal glycosyltransferase activity. | ||||||
(Z)-Pugnac | 132489-69-1 | sc-204415A sc-204415 | 5 mg 10 mg | $224.00 $380.00 | 3 | |
An O-GlcNAcase inhibitor, PUGNAc can increase O-GlcNAcylation levels, potentially competing with GalNAc-TL4 mediated glycosylation by altering substrate availability and glycosylation patterns. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Inhibits protein transport from the ER to the Golgi apparatus, potentially reducing the substrate pool for GalNAc-TL4 and indirectly inhibiting its glycosylation activity. | ||||||